A detailed history of State Of Tennessee, Treasury Department transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, State Of Tennessee, Treasury Department holds 100,943 shares of VRTX stock, worth $52.2 Million. This represents 0.18% of its overall portfolio holdings.

Number of Shares
100,943
Previous 106,685 5.38%
Holding current value
$52.2 Million
Previous $44.6 Million 6.1%
% of portfolio
0.18%
Previous 0.17%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$392.81 - $485.53 $2.26 Million - $2.79 Million
-5,742 Reduced 5.38%
100,943 $47.3 Million
Q1 2024

May 14, 2024

SELL
$407.69 - $446.08 $3.21 Million - $3.51 Million
-7,871 Reduced 6.87%
106,685 $44.6 Million
Q4 2023

Feb 14, 2024

SELL
$343.0 - $410.68 $26.8 Million - $32.1 Million
-78,099 Reduced 40.54%
114,556 $46.6 Million
Q2 2023

Aug 15, 2023

BUY
$314.42 - $351.91 $530,426 - $593,672
1,687 Added 0.88%
192,655 $67.8 Million
Q1 2023

May 12, 2023

BUY
$283.23 - $323.1 $4.41 Million - $5.03 Million
15,582 Added 8.88%
190,968 $60.2 Million
Q4 2022

Feb 15, 2023

SELL
$285.76 - $321.48 $19.5 Million - $21.9 Million
-68,077 Reduced 27.96%
175,386 $50.6 Million
Q3 2022

Jan 26, 2023

SELL
$273.83 - $305.53 $2.47 Million - $2.76 Million
-9,031 Reduced 3.58%
243,463 $70.5 Million
Q2 2022

Aug 15, 2022

SELL
$234.96 - $292.55 $13.3 Million - $16.5 Million
-56,485 Reduced 18.28%
252,494 $71.2 Million
Q1 2022

May 11, 2022

BUY
$221.42 - $260.97 $14.6 Million - $17.2 Million
65,837 Added 27.08%
308,979 $80.6 Million
Q4 2021

Feb 15, 2022

BUY
$177.01 - $223.45 $8.74 Million - $11 Million
49,402 Added 25.5%
243,142 $53.4 Million
Q3 2021

Nov 12, 2021

SELL
$181.39 - $202.99 $31.8 Million - $35.6 Million
-175,176 Reduced 47.48%
193,740 $35.1 Million
Q2 2021

Aug 11, 2021

BUY
$187.49 - $221.1 $8.94 Million - $10.5 Million
47,692 Added 14.85%
368,916 $74.4 Million
Q1 2021

May 10, 2021

BUY
$207.02 - $241.31 $6.62 Million - $7.72 Million
31,996 Added 11.06%
321,224 $69 Million
Q4 2020

Feb 09, 2021

SELL
$207.01 - $276.09 $36.3 Million - $48.5 Million
-175,534 Reduced 37.77%
289,228 $68.4 Million
Q3 2020

Nov 16, 2020

BUY
$255.65 - $303.1 $54 Million - $64.1 Million
211,385 Added 83.43%
464,762 $126 Million
Q2 2020

Aug 13, 2020

BUY
$225.48 - $295.8 $3.88 Million - $5.1 Million
17,227 Added 7.29%
253,377 $73.6 Million
Q1 2020

May 15, 2020

BUY
$199.77 - $247.81 $11.6 Million - $14.4 Million
58,231 Added 32.73%
236,150 $56.2 Million
Q4 2019

Feb 06, 2020

BUY
$166.71 - $223.91 $2.36 Million - $3.16 Million
14,130 Added 8.63%
177,919 $39 Million
Q3 2019

Oct 30, 2019

BUY
$166.23 - $187.09 $17.4 Million - $19.6 Million
104,770 Added 177.52%
163,789 $27.7 Million
Q2 2019

Aug 12, 2019

SELL
$164.61 - $190.37 $814,984 - $942,521
-4,951 Reduced 7.74%
59,019 $10.8 Million
Q1 2019

May 13, 2019

SELL
$163.73 - $194.7 $369,374 - $439,243
-2,256 Reduced 3.41%
63,970 $11.8 Million
Q4 2018

Feb 11, 2019

SELL
$151.91 - $192.21 $52.1 Million - $65.9 Million
-342,797 Reduced 83.81%
66,226 $11 Million
Q3 2018

Nov 13, 2018

BUY
$167.73 - $192.74 $22.8 Million - $26.2 Million
135,825 Added 49.72%
409,023 $78.8 Million
Q2 2018

Aug 14, 2018

BUY
$145.72 - $169.96 $8.76 Million - $10.2 Million
60,108 Added 28.21%
273,198 $46.4 Million
Q1 2018

May 11, 2018

BUY
$151.6 - $177.13 $4.06 Million - $4.74 Million
26,765 Added 14.36%
213,090 $34.7 Million
Q4 2017

Feb 12, 2018

BUY
$137.28 - $155.55 $1.75 Million - $1.98 Million
12,727 Added 7.33%
186,325 $27.9 Million
Q3 2017

Nov 01, 2017

BUY
$148.13 - $162.24 $25.7 Million - $28.2 Million
173,598
173,598 $26.4 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $133B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track State Of Tennessee, Treasury Department Portfolio

Follow State Of Tennessee, Treasury Department and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Of Tennessee, Treasury Department, based on Form 13F filings with the SEC.

News

Stay updated on State Of Tennessee, Treasury Department with notifications on news.